NEWS & EVENTS
News & Events
Press Release

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL) December 22, 2017

Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530(tenalisib), a highly selective dual PI3K delta/ gamma inhibitor for the treatment of patients with relapsed/ refractory peripheral T-cell lymphoma (PTCL) December 09, 2017

Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at 59th ASH Annual Meeting, Atlanta, GA (December 05, 2017)

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium releaseactivated calcium (CRAC) channel at AACR-NCI-EORTC International Conference, USA(October 24, 2017)

Rhizen Pharmaceuticals Announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3Kdelta/gamma Inhibitor (December 09, 2015)

Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma. (September 22, 2015)

Rhizen Pharmaceuticals S.A. to present Phase 1 clinical and preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in hematological malignancies (December 2, 2014)

Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma (November 18, 2014)

Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor. (September 23, 2014)


Events
Rhizen to present at at 59th ASH Annual Meeting, Atlanta, GA (December 09-12, 2017)